GYNECOLOGY: GYNECOLOGIC ONCOLOGYUse of Cannabinoids in Cancer Patients: A Society of Gynecologic Oncology (SGO) Clinical Practice StatementWhitcomb, B.; Lutman, C.; Pearl, M.; Medlin, E.; Prendergast, E.; Robison, K.; Burke, W.Author Information University of Connecticut Health, The Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT (B.W.); Mission Hope Cancer Center, Santa Maria, CA (C.L.); Stony Brook Medicine, Stony Brook, NY (M.P., W.B.); Lancaster General Health, Penn Medicine, Lancaster, PA (E.M.); Minnesota Oncology, Minneapolis, MN (E.P.); and Women & Infants Hospital, Providence, RI (K.B.) Obstetrical & Gynecological Survey: July 2020 - Volume 75 - Issue 7 - p 408-409 doi: 10.1097/OGX.0000000000000812 Buy Metrics Abstract (Abstracted from Gynecol Oncol 2020;157:307–311) A comprehensive report published by the National Academies of Science, Engineering and Medicine in 2017 concluded that there exists “conclusive or substantial evidence that cannabis or cannabinoids are effective” in treatment of chronic pain in adults and as an antiemetic agent in patients undergoing chemotherapy. Despite this recommendation, barriers remain to determining the significant short- and long-term health effects of cannabis. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.